Before the visit Considering a thymalfasin offer

StartStudy results

What did the studies actually find?

A promising headline can leave out the comparison that matters. Look for what happened to people, and what the study could not answer.

The broad review left benefit unproven.

In 2024, the FDA review examined 12 possible uses of thymosin alpha-1 and found insufficient evidence for each.

The FDA is the U.S. drug review agency. Its finding does not prove the substance can never work.

The sepsis results explain conflicting headlines.

Sepsis is a life-threatening response to an infection. These studies involved people being treated in hospitals.

Their results do not answer whether a healthy adult benefits from thymosin alpha-1.

An early hint, then a firmer test.

The ETASS trial in 2013 studied 361 patients and hinted at fewer deaths with the drug.

The larger TESTS trial, published in BMJ in 2025, enrolled 1,106 patients and found no clear reduction in deaths.

What the larger trial counted.

The trial tracked deaths within 28 days.

  • About 23 of every 100 died in the drug group.
  • About 24 of every 100 died in the comparison group.
  • The comparison group received a placebo: a dummy shot with no active drug.

The TESTS authors declared support from the drug’s maker, SciClone Pharmaceuticals.

Combining studies did not settle the question.

In 2025, a journal review combined results from 11 trials of sepsis care.

Taken together, the trials suggested that fewer people died.

The reviewers also checked two smaller sets of trials. First, they kept only trials they rated higher quality, meaning they judged the results more trustworthy. That set did not show a clear benefit. Then they kept only trials run at several hospitals. That set did not show a clear benefit either. The apparent benefit depended on which trials were included.